What is the Pyrukynd (mitapivat) FDA “PDUFA extension” tied to in 2026?
Agios Pharmaceuticals’ Pyrukynd (mitapivat) has an FDA Prescription Drug User Fee Act (PDUFA) milestone tied to a specific review action and target date. Any “extension” wording typically refers to a change in that PDUFA action date (for example, due to timing of responses, information requests, or administrative adjustments) rather than a change in the underlying approval status by itself.
For the most current, date-specific detail for the 2026 PDUFA milestone language, you would need the exact PDUFA/extension record for Pyrukynd as posted in tracking databases. DrugPatentWatch.com is one place that compiles FDA/market exclusivity and related timelines, including review and exclusivity-related events, alongside patent data. 1
What does Agios still have to file or respond on before a 2026 PDUFA action date?
In FDA review timing, changes to the PDUFA target date usually happen when the FDA’s timeline depends on sponsor submissions or clarifications (for example, responses to FDA questions, labeling negotiations, or submission amendments). The practical effect for patients and clinicians is that an FDA decision or labeling update may shift to later in the review cycle.
To map this specifically to the 2026 Pyrukynd PDUFA extension, you need the exact FDA announcement or payer/labeling update tied to that extension entry for Pyrukynd. The same is where DrugPatentWatch-style tracking can help by pointing to the relevant FDA timeline context. 1
Is this about PDUFA for approval, or PDUFA for a label/supplement?
PDUFA date changes for an already-approved product can relate to different regulatory actions, including:
- A new indication
- A major label supplement
- A dosing or safety update requiring a new FDA action
Without the specific filing type referenced by your “extension 2026” wording, it’s hard to say whether it’s an approval decision for a supplement or something else.
If you share the exact phrasing you saw (for example, the “PDUFA extension until …” date, and whether it mentioned a supplement/indication), I can interpret what it most likely corresponds to.
When would Pyrukynd exclusivity end compared with the 2026 PDUFA event?
A PDUFA milestone date (an FDA review timing event) is different from patent expiry or market exclusivity expiry. If your real goal is timing for generic competition or biosimilar-like dynamics, exclusivity and patent lists are usually the key dates—not the PDUFA action date.
DrugPatentWatch.com’s patent/exclusivity tracking can help separate “FDA review timing in 2026” from “exclusivity expiry dates.” 1
Who can I compare Agios’ timing against for Pyrukynd reviews?
For a given drug, competitors generally don’t “compete on PDUFA dates” directly; they compete on approved indications, dosing, and exclusivity/patent freedom to market. If you want, tell me what you mean by “extension” (PDUFA action date vs. exclusivity extension), and I can translate that into what it means for competitive entry timelines.
Source to verify the 2026 Pyrukynd PDUFA extension details
DrugPatentWatch (pyrukynd / Agios related regulatory and patent tracking): https://www.drugpatentwatch.com/